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Abstract
Purpose To study the effectiveness of prophylactic
embolization of hepaticoenteric arteries to prevent gas-
trointestinal complications during radioembolization.
Methods A PubMed, Embase and Cochrane literature
search was performed. We included studies assessing both
a group of patients with and without embolization.
Results Our search revealed 1401 articles of which title
and abstract were screened. Finally, eight studies were
included investigating 1237 patients. Of these patients, 456
received embolization of one or more arteries. No
difference was seen in the incidence of gastrointestinal
complications in patients with prophylactic embolization of
the gastroduodenal artery (GDA), right gastric artery
(RGA), cystic artery (CA) or hepatic falciform artery
(HFA) compared to patients without embolization. Few
complications were reported when microspheres were
injected distal to the origin of these arteries or when
reversed flow of the GDA was present. A high risk of
confounding by indication was present because of the non-
randomized nature of the included studies.
Conclusion It is advisable to restrict embolization to
those hepaticoenteric arteries that originate distally or close
to the injection site of microspheres. There is no conclusive
evidence that embolization of hepaticoenteric arteries
influences the risk of complications.
Keywords Radioembolization  Yttrium 
Embolization  Gastroduodenal artery  Right gastric
artery  Cystic artery  Hepatic falciform artery 
Complications
Introduction
Radioembolization has gained widespread usage for the
management of both primary and secondary, unre-
sectable and chemotherapy refractory liver malignancies.
Because healthy liver parenchyma is mostly supplied by the
portal vein, hepatic tumors can be selectively targeted by
injection of yttrium-90 (90Y) microspheres in the hepatic
arteries. Particles of resin or glass, containing millions of the
radioactive 90Y microspheres, are injected into the liver via
the hepatic artery. These microspheres might disperse to
surrounding organs through hepaticoenteric arteries, such as
the gastroduodenal artery (GDA), right gastric artery (RGA),
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cystic artery (CA) or hepatic falciform artery (HFA). Non-
target embolization might subsequently result in complica-
tions, including gastrointestinal ulceration (0.7–28.6 %) [1–
4] and cholecystitis (0.6–6.0 %) [5, 6]. Non-target
embolization can be prevented through prophylactic
embolization of hepaticoenteric arteries during a pretreat-
ment angiography after which technetium-99m-labeled
macroaggregated albumin (99mTc-MAA) can be injected as
an additional screening procedure.
Experienced centers increasingly omit the occlusion of
the vessels originating proximal to the microsphere injec-
tion site. Several studies have shown that collateralization
and recanalization of arteries can occur after occlusion of
hepaticoenteric arteries, opposing the initial purpose of this
procedure [7–9] and bringing its benefit into question.
Therefore, the purpose of this review is to evaluate the
evidence of prophylactic embolization of hepaticoenteric
arteries (i.e. GDA, RGA, CA or HFA) to prevent non-target
deposition of microspheres and subsequent complications
in patients with liver malignancies undergoing hepatic
radioembolization.
Methods
Reporting of this review was conducted according to the
PRISMA guidelines [10].
Search Strategy
A PubMed, Embase and Cochrane literature search was
performed on 22 May 2015 to identify all articles related to
the use of embolization of hepaticoenteric arteries in
patients with liver malignancies undergoing radioem-
bolization. Search terms used to identify these articles were
combinations of ‘liver cancer’, ‘radioembolization’, ‘pro-
phylactic embolization’, all synonyms and MeSH or
Emtree terms. After full text screening, references of
reviews and identified articles were screened to find addi-
tional articles.
Study Selection
After the removal of duplicates, titles and abstracts were
reviewed independently by two reviewers (the first group by
A.B. and C.D., the second group by A.L. and C.V.). Full text
was obtained if title and abstract met the predetermined in-
and exclusion criteria. Disagreements were resolved on
consensus-based discussion with all four reviewers. Articles
were included in which: (1) patients with liver malignancies
undergoing radioembolization were studied, (2) prophylac-
tic embolization of hepaticoenteric arteries was reported, (3)
gastrointestinal complications or non-target embolization on
imaging was used as outcome, (4) both a group of patients
with and without embolization were assessed and (5) the
authors reported results in English, German or Dutch. Case
reports, animal studies, in vitro studies, congress abstracts
and reviews were excluded.
Risk of Bias
The quality of the studies was assessed by a critical apprai-
sal that was specifically designed for our search and inclu-
ded studies. Studies were independently appraised on
validity by four reviewers (A.B., A.L., C.D., C.V.) on the
following items: (1) study design characteristics: study type,
data collection, funding and potential role of funders in
study; (2) standardization: sufficient description of indica-
tion for treatment, procedure of embolization, assessment of
outcome and (3) loss to follow-up: routine imaging or
endoscopy was preferred, but routine clinical assessment
was also considered to be of value.
Data Extraction
Data extraction was performed by two independent
reviewers. The following data were extracted from the
studies: specification of the embolized arteries, the indi-
cation for embolization, study size, number of patients who
were embolized or not, results of post-treatment imaging
and the number and type of complications in each patient
group.
No meta-analysis could be performed due to hetero-
geneity of the included study populations, the variety of
indications used for embolization and the different
methodologies used for the assessment of outcomes.
Results
The search strategy resulted in 1041 articles. Thirty-nine of
these articles were screened on full-text. The check for
references and related citations did not yield new articles.
Eight studies fulfilled the eligibility criteria (Fig. 1) and
were assessed for their quality (Fig. 2) [11–18].
The studies were all single-centered, retrospective and
non-randomized in nature. There was one letter to the
editor [11]. The risk of conflict of interest of all studies was
low.
Paprottka et al. [17] and Powerski et al. [15] were
considered to be of best quality: both studied a large cohort
with even distribution between patients who were embo-
lized or not, and both included a well-defined and extensive
follow-up period (respectively 24 weeks and 12 months)
(Fig. 2).
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Study characteristics and results are listed in Table 1.
The included studies investigated a total of 1237 patients
of whom 456 received embolization of one or more
arteries. Overall, 55 out of 456 embolized patients expe-
rienced any type of complication (i.e. adverse events
possibly, probably or definitely related to extrahepatic
deposition of activity) after radioembolization, varying
from pain in the right upper abdominal quadrant to gas-
trointestinal ulceration. In the non-embolized group, 34
out of 781 patients experienced complications of any
kind. The risk differences between patients in the embo-
lized group and patients in the non-embolized group
varied from 0 to 12 %.
Indication for Embolization
The studies were subjected to confounding by indication
(the determinant is present if a perceived high risk of poor
prognosis is an indication for treatment) [19], because the
decision to occlude hepaticoenteric arteries depended on
specific clinical situations, e.g. the infusion of micro-
spheres proximal to the origin of the hepaticoenteric
arteries [11–18].
All studies gave a detailed description of the pretreat-
ment preparations, the treatment itself and the equipment
and materials used, except for Hamoui et al. [11] who
specified only the type of microspheres used.
Records identified through  
databases searching 























Additional records identified 
through other sources 
(n = 0)
Records after duplicates removed 
(n =1401) 
Records screened on 
title/abstract 
(n = 1401) 
Records excluded 
(n = 1362) 
Full-text articles assessed 
for eligibility 
(n =39) 
Full-text articles excluded 
(n =31) 
Studies included in 
qualitative synthesis 
(n = 8) 
Fig. 1 Flow chart of literature search
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Assessment of Outcome
Two studies [14, 15] used radiological follow-up, physical
examination and blood tests to identify complications due
to non-target radioembolization. Theysohn et al. [14] per-
formed a CT-scan of the liver 28 days after radioem-
bolization to detect changes like thickening of the
gallbladder wall or free fluid in the gallbladder bed. In the
study by Powerski et al. [15], patients received an MRI of
the liver on three occasions to assess gallbladder wall
thickness and free fluid adjacent to the gallbladder: before
pretreatment angiography, immediately after treatment and
6 weeks after treatment. Additionally, bremsstrahlung
SPECT was used to detect radioactive microspheres in
gallbladder tissue [15].
Five studies used clinical and/or laboratory parameters
during follow-up [12, 13, 16–18]. Paprottka et al. [17] was
the only study that classified the clinical complications of
non-target embolization using standardized criteria, namely
the National Cancer Institute’s Common Terminology
Criteria for Adverse Events (CTCAEv3.0) [20] and dif-
ferentiated between early complications (within a week
after treatment) and late complications (up to 6 months).
Complications of grade C3 were considered clinically
relevant.
Hamoui et al. did not specify their follow-up procedure,
but did seek for histologic evidence of microsphere depo-
sition in patients with gastric ulcers [11].
Timing of Follow-Up
Follow-up consisted of frequent clinical assessment in five
studies [12, 13, 15, 17, 18]: every 2–6 weeks, up to 2 [13],






























































Daghir13 ± – – ± + + ± +
Cosin12 – – – – + + ± –
Hamoui11 ± – – – + – – –
Theysohn14 ± – – + + + + –
Powerski15 ± – – ± + + + –
Ahmadzedefar18 ± – – + + + ± –
Schelhorn16 ± – – + + + – –
Paprottka17 ± – – + + + ± –
Legend
Study type
+ Randomized controlled trial
± Cohort study







Funding and potential role of funders
+ No
± Yes
– Not reported 
Indication for treatment 
Criteria for occlusive therapy are
+ Well defined per protocol
– Not standardized or insufficiently reported
Procedure 
Embolization therapy procedure was
+ Well defined per protocol 
– Not standardized or insufficiently reported
Assessment of outcome 
+ Routinely by imaging or endoscopy





– > 20% or not reported
Fig. 2 Critical appraisal of selected articles
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studies did not specify the frequency of post-procedural
follow-up visits or instructed patients to contact the hospital
in case of complaints [11, 14, 16]. One study [13] mentioned
loss to follow-up of patients, but did not take this into account
during analysis or interpretation of the data.
Resin and Glass Microspheres
Two studies [11, 14] used glass microspheres while all
other studies used resin microspheres [12, 13, 15–18].
Gastrointestinal Complications
Three studies investigated embolization of the GDA or
RGA [11–13] when applying specific criteria (Fig. 3).
None found a significant difference in the occurrence of
complications between the study arms.
The first study, Daghir et al. [13], reported on a cohort of
82 patients in whom the GDA was not embolized if it had
reversed (i.e., hepatofugal) flow. None of the 11 patients
with reversed flow developed complications related to
extrahepatic deposition (gastroduodenal bleeding, ulcera-
tion or pancreatitis), but 7 out of those 11 patients expe-
rienced early toxicity of the treatment, including liver
derangement, radiation hepatitis, anemia, nausea or
postembolization syndrome. Within the group of patients
with antegrade flow (n = 71), two cases of gastroduodenal
ulceration and one case of gastroduodenal bleeding were
reported. In two of these three cases, a culprit vessel could
be found.
The second, Cosin et al. [12], embolized the RGA when
it was visible on angiography and close to the injection
position (distance not specified). Neither one of the nine
embolized nor one of the 18 non-embolized patients
showed any complications.
The third, Hamoui et al. [11], posed that injection distal
to the GDA or RGA does not require embolization, since
the complication rate was low (n = 2, 1 % gastrointestinal
ulcers). After endoscopic biopsy, microspheres were pre-
sent in the gastric wall of one patient, but not in the other,
who had a history of peptic ulcer disease. The complication
rate of the embolized group was not reported.
Fig. 3 Typical angiography in
a patient who underwent coil-
embolization of the
gastroduodenal artery (GDA)
and right gastric artery (RGA).
A Digital subtraction
angiography (DSA) of the GDA
(white arrowhead) on pre-
treatment angiography. B DSA
with appearance of the RGA
(black arrowhead) after coil-
embolization of the GDA.
C DSA with catheter placement
in the RGA. D DSA after
successful coil-embolization of
the GDA and RGA
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Biliary Complications
Three studies [13–15] reported on the need to embolize the
cystic artery. In the first, Theysohn et al. [14] embolized
patients’ cystic artery if the uptake of 99mTc-MAA in the
gallbladder was larger than in the liver and found one
complication in the group that was embolized (n = 20).
In the second, Powerski et al. [15] performed emboliza-
tion if the catheter could easily enter the cystic artery. The
amount of 90Y uptake in the gallbladder wall was lower after
embolization, but more patients complained of right upper
quadrant pain (22 vs. 10 %). Two patients developed
cholecystitis in the embolized subgroup (n = 68), and one
in the non-embolized subgroup (n = 37).
In the third, Daghir et al. [13] mentioned they did not
routinely embolize the cystic artery; however, they did not
specify the number of patients in whom the cystic artery
was embolized or which precautions they undertook to
avoid the cystic artery during delivery of the radioembolic
material. No signs of gallbladder inflammation or infarc-
tion were seen in both patient groups.
Hepatic Falciform Artery
Embolization of the hepatic falciform artery was evaluated
in two small studies [16, 18]. In these studies, the hepatic
falciform artery could be identified in only 28 out of 798
patients (3.5 %).
In the first, by Ahmadzadehfar et al. [18], tracer
accumulation in the anterior abdominal wall was seen in
17 (9.3 %) patients. The hepatic falciform artery could be
identified and embolized in only one patient, who sub-
sequently did not show 90Y uptake in the anterior
abdominal wall on bremsstrahlung SPECT/CT. Out of the
16 other patients that showed tracer accumulation in the
anterior abdominal wall on 99mTc-MAA images prior to
radioembolization, only 9 (56 %) showed uptake in the
abdominal wall on post-treatment imaging. One of those
nine patients developed abdominal muscular pain above
the umbilicus. Furthermore, all other hepaticoenteric
arteries were also embolized, but the occurrence of
complications, other than abdominal muscular pain, was
not reported.
In the second, Schelhorn et al. [16] embolized the
hepatic falciform artery with coils or gelfoam in a subgroup
of five patients. In six patients no embolization was per-
formed, but neither subgroup of patients developed com-
plications. However, unlike Ahmadzadehfar et al. [18],
they used ice packs to induce vasoconstriction in the
anterior abdominal wall during 90Y administration to pre-
vent complications in patients showing a persistently patent
HFA that could not be embolized.
Other
Paprottka et al. [17] embolized all hepaticoenteric branches
originating distal to the injection position during the
radioembolization procedure. There were significantly less
early toxicities (including nausea, vomiting, abdominal pain
and fever) in the group without embolization (4 %) com-
pared to the group with embolization (13 %). The milder
(grade 1 and 2) complications also occurred significantly
less in the group without embolization (35 vs. 60 %).
Discussion
The purpose of this literature review was to summarize the
evidence for prophylactic embolization of hepaticoenteric
arteries to prevent complications after radioembolization.
We identified eight comparative, non-randomized, retro-
spective studies. In general, the rate of gastro-intestinal
complications after radioembolization was low in both the
embolized and non-embolized group. None of the included
studies showed evidence in favor of routine performance of
prophylactic embolization. However, they did state that
when using certain criteria for embolization (Table 1) it
appears to be safe to refrain from prophylactic emboliza-
tion. For example, Paprottka et al. [17] states that coiling
might be abandoned if the catheter for applying the
microspheres has a distance of at least 2 cm to the first
proximal extra-hepatic artery.
The most important limitation of this review is the lack
of randomized controlled trials and prospective studies.
Embolization of hepaticoenteric arteries was only per-
formed in patients who are at higher risk for complications,
which was determined by the hepaticoenteric vascular
anatomy. The risk differences that appear to be in favor of
non-embolized patients are distorted by confounding by
indication, as the study groups are not comparable.
Therefore, the evidence is limited and it is only possible to
draw conclusions regarding the necessity of prophylactic
embolization to decrease the risk of complications in
specific situations.
Also, complications may have been underestimated
because most studies did not routinely perform follow-up,
post-treatment imaging or endoscopy [11–14, 17]. Even
thoughwe developed a quality scoring system specifically for
this review to assess these kinds of methodological aspects,
thismay not have captured all the relevant aspects adequately.
Furthermore, the incidence of complications in both
embolized and non-embolized patients may partly be
explained by the fact that the occurrence of gastrointestinal
complications does not only depend on extrahepatic micro-
sphere deposition, but also on patient characteristics such as
a history of gastro-intestinal ulcerative disease. One study
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[11] took histologic evidence of the affected organs into
account and could, and thus, proved that the gastro-intestinal
complications were attributable to extrahepatic microsphere
deposition, rather than other causes. This implicates that the
outcomemeasures usedwere prone to bias. Furthermore, it is
questionable whether symptoms such as pain are truly
attributable to non-target radioembolizationwhen they could
also be caused by, for example, ischemia of tumor or liver
tissue: post-radioembolization syndrome. Misidentification
of hepaticoenteric arteries on pre-treatment angiography or
the inability to occlude hepaticoenteric arteries due to small
size may also have contributed to the incidence of compli-
cations in the non-embolized group [11, 13].
Prophylactic embolization might not always be suffi-
cient to prevent non-target deposition of microspheres as
four studies reported complications in embolized patients.
A possible explanation for this problem is the occurrence
of recanalization of embolized arteries, collateral formation
or opening of formerly hypoperfused vessels. Several
studies report an incidence of recanalization and collateral
development of 11–44 % in coiled patients [7–9]. Perhaps
timing of prophylactic embolization during the radioem-
bolization procedure itself, rather than during pretreatment
angiography, might reduce the incidence of recanalization
and collateral development. Of the studies selected in this
review, only Paprottka et al. [17] and Theysohn et al. [14]
described this approach. Lastly, extrahepatic deposition
could occur because of stasis during administration, but the
included studies did not investigate this [21].
Compared to glass microspheres, resin micropsheres
have a significant embolic effect, which often leads to
arterial occlusion, which, in turn, increases the risk of non-
target radioembolization through backflow of microspheres
[22, 23]. Theoretically, prophylactic embolization might be
less important when using glass microspheres, but our
study does not provide sufficient data to support this
hypothesis. Two studies directly comparing both micro-
spheres show no significant differences in toxicity and
survival rates [24, 25].
A significant improvement in the detection of hepati-
coenteric shunting can be achieved by using cone beam CT
before radioembolization in addition to digital subtraction
angiography [26–28]. The potential role and impact of cone
beam CT are not assessed in this review, because none of the
included studies mentioned the use of cone beamCT for pre-
treatment planning. It is expected that using a cone beam CT
will reduce the incidence of hepaticoenteric complications.
Future research could provide a higher level of evidence
for the criteria to be used for prophylactic embolization.
The most important aspect is the comparability of patient
groups. There is no need for further studies comparing
patients with an indication for embolization to patients
without, but there is a need for a study comparing
embolization within those groups. For this, a prospective
study that uses a pre-defined protocol that defines the
indication to embolize is advisable (e.g. minimal distance
between catheter tip and hepaticoenteric arteries).
Lastly, the need to embolize hepaticoenteric arteries
before radioembolization may be further eliminated in the
future since promising results of alternative techniques to
prevent non-target deposition of microspheres, such as
temporary balloon occlusion and anti-reflux catheters, have
been published recently [29–35].
Conclusion
There is no conclusive evidence supporting prophylactic
embolization of hepaticoenteric arteries directly influences
the risk of complications. According to the best available
evidence, refraining from embolization of the GDA, RGA
and CA is justified when the catheter tip can be placed
distal to the origin of these arteries or when reversed flow is
present in the GDA. The hepatic falciform artery can be
embolized if a large uptake in the abdominal wall is seen.
Using these criteria, the risk of complications is low.
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